Predicting response to acetylcholinesterase inhibitor treatment in Alzheimer disease: Has the time come?

Nature Clinical Practice Neurology

Volumn 5, Issue 3, 2009, Pages 128-129

  Feldman, Howard H ^a,b   Jacova, Claudia ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

ALZHEIMER DISEASE; COGNITION; COHORT ANALYSIS; FOLLOW UP; HUMAN; MINI MENTAL STATE EXAMINATION; NOTE; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 62549161688     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro1007     Document Type: Note

References (7)

1. Kaduszkiewicz H et al. (2005) Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of randomised clinical trials. BMJ 331: 321-327
2. Knopman D (2006) Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying. Alzheimer Dement 2: 147-149
3. Klunk WE et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319
4. Brys M et al. (2007) Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging [doi:10.1016/j.neurobiolaging.2007.08.010]
5. Wattmo C et al. (2008) Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting. Dement Geriatr Cogn Disord 26: 203-211
6. Stern RG et al. (1994) A longitudinal study of Alzheimer's disease: Measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 151: 390-396
7. Van Der Putt R et al. (2006) Effectiveness of acetylcholinesterase inhibitors: Diagnosis and severity as predictors of response in routine practice. Int J Geriatr Psychiatry 21: 755-760